6533b82efe1ef96bd129287f

RESEARCH PRODUCT

Liver Transplantation for Hepatocellular Carcinoma After Yttrium Therapy: A Case Report

Georgios C. SotiropoulosGeorge SgourakisIoannis FouzasErnesto P. MolmentiJ. ErtlG. AntochHauke LangSusanne BeckebaumAndreas PaulC. E. BroelschK.m. NowakPhilip Hilgard

subject

Malemedicine.medical_specialtyCarcinoma HepatocellularTime FactorsCirrhosismedicine.medical_treatmentLiver transplantationMicrospheremedicineHumansYttrium RadioisotopesChemoembolization TherapeuticAged 80 and overTransplantationbusiness.industryLiver NeoplasmsCancerTreatment optionsMiddle Agedmedicine.diseaseCombined Modality TherapyLiver TransplantationTumor recurrenceSurgeryTreatment Outcomesurgical procedures operativeHepatocellular carcinomaSurgerybusinessLiver cancer

description

Yttrium-90 microspheres constitute one of the most recent treatment options for hepatocellular carcinoma (HCC) in the setting of cirrhosis. As such, their spectrum of indication is not yet fully established. Herein, we have reported the case of a patient with HCC beyond the listing criteria for liver transplantation (OLT) who was treated preoperatively with selective transarterial chemoembolization and yttrium-90 microspheres. He was subsequently transplanted with a liver from an 81-year-old donor allocated through Eurotransplant as a "rescue offer." The posttransplant course was uneventful. Pathologic examination revealed a multifocal, well-differentiated pT2 tumor with no vascular invasion. The patient is currently alive and in good condition at 14 months posttransplant, with no evidence of tumor recurrence by a current computed tomography scan. This report provided encouraging information on the potential of yttrium-90 microspheres as a bridging option before OLT for multifocal HCC.

yearjournalcountryeditionlanguage
2008-12-01Transplantation Proceedings
https://doi.org/10.1016/j.transproceed.2008.09.036